Nurix closes $3B Roche deal to co-develop bexobrutideg
Nurix Therapeutics, Inc. has closed a global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, a BTK degrader. Nurix receives $700 million upfront and is eligible for up to $2.3 billion in milestones. The companies will share development costs and U.S. profits, while Roche handles ex-U.S. commercialization.
*this image is generated using AI for illustrative purposes only.
Nurix Therapeutics, Inc. has closed its global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader. The agreement follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. This partnership positions Nurix to leverage Roche's global capabilities to advance bexobrutideg across malignant hematology, immunology, and neurology.
Under the terms of the agreement, Nurix will receive an upfront cash payment of $700 million and is eligible to receive development, regulatory, and sales milestones for potential total payments of up to $2.3 billion. Development costs will be shared 40% by Nurix and 60% by Roche. The parties will equally split profits and losses from U.S. commercialization, while Roche will handle commercialization outside the United States, with Nurix eligible to receive royalties ranging from the low- to high-teens.
Financial Terms
| Component | Details |
|---|---|
| Upfront Payment | $700 million |
| Potential Milestones | Up to $2.3 billion |
| Development Cost Share | Nurix: 40%, Roche: 60% |
| U.S. Profit/Loss Share | Equal split |
| Ex-U.S. Royalties | Low- to high-teens |
Nurix and Roche will jointly advance a broad clinical development program for bexobrutideg. The program includes ongoing and planned studies in chronic lymphocytic leukemia (CLL), additional B-cell malignancies, multiple sclerosis (MS), and chronic spontaneous urticaria (CSU).
Clinical Development Plan
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule degrader of BTK. It is currently being evaluated in the DAYBreak CLL-201 clinical trial, a pivotal single-arm Phase 2 study in patients with relapsed/refractory CLL, and in the NX-5948-301 Phase 1a/1b clinical trial in patients with relapsed/refractory B-cell malignancies.
Additional planned trials include the DAYBreak CLL-306 Phase 3 trial comparing bexobrutideg to pirtobrutinib in relapsed/refractory CLL, and the NX-5948-203 Phase 1/2 trial assessing the combination of bexobrutideg with venetoclax, with or without an anti-CD20 antibody, in relapsed/refractory and treatment-naive CLL. A new tablet formulation is also being evaluated in a first-in-human study in healthy volunteers to support future development in immunology and neurology indications.
"This global collaboration marks a transformational moment for Nurix and the field of targeted protein degradation," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "With Roche as our partner, we are uniquely positioned to realize the full potential of bexobrutideg across oncology, immunology and neurology."
How will the upcoming Phase 3 trial comparing bexobrutideg to pirtobrutinib impact the competitive landscape for relapsed/refractory CLL treatments?
What are the potential implications of the new tablet formulation for patient adherence and expansion into immunology and neurology indications?
How might the 40/60 development cost split influence Nurix's R&D budget and prioritization of other pipeline programs?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
